Author

M. Glass

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Assay:metabolomics· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2

Frequent Co-Authors

A. Sinz· 2 shared C. Ihling· 2 shared A. Adams· 1 shared A. Schott· 1 shared A. Yennemadi· 1 shared B. Rochelle· 1 shared C. Assmann· 1 shared C. Beyer· 1 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Sinz

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Mannose Supplementation Curbs Liver Steatosis and Fibrosis in Murine MASH by Inhibiting Fructose Metabolism

J. Hong, Y. Carbajal, J. Trotman, M. Glass, V. Sclar, I. L. Alter, P. Zhang, L. Wang, L. Chen, M. Petitjean, S. L. Friedman, C. DeRossi, J. Chu

This study shows that mannose reduces liver steatosis and fibrosis in MASH by inhibiting fructose metabolism, offering a potential therapeutic approach.

bioRxiv · Jan 17, 2024 · PreprintCell Biology

Chronic IFNα treatment induces leukopoiesis, increased plasma succinate and immune cell metabolic rewiring

G. Leisching, A. Yennemadi, J. Keane, C. De Pasquale, M. Bianchi, M. Glass, G. Jameson

This study shows that chronic IFNα treatment in rats causes hypermetabolic immune cells, increased plasma succinate, and impaired bacterial response.

bioRxiv · Oct 17, 2022Immunology

RUNX1 isoform disequilibrium in the development of trisomy 21 associated myeloid leukemia

S. Gialesaki, D. Brauer-Hartmann, R. Bhayadia, O. Alejo-Valle, H. Issa, E. Regenyi, C. Beyer, M. Labuhn, C. Ihling, A. Sinz, M. Glass, S. Huttelmaier, S. Matzk, L. Schmid, F. J. Struwe, , J.-H. Klusmann

This study identifies RUNX1 isoform imbalance as a key driver of trisomy 21-associated myeloid leukemia and shows that restoring this balance can reverse leukemogenesis.

bioRxiv · Mar 7, 2022 · PreprintCancer Biology

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

N. Bley, A. Schott, S. Mueller, D. Misiak, M. Lederer, T. Fuchs, C. Assmann, M. Glass, C. Ihling, A. Sinz, N. Pazaitis, C. Wickenhauser, M. Vetter, O. Ungurs, H.-G. Strauss, , S. Huettelmaier

This study identifies IGF2BP1 as a driver of invasive growth in ovarian cancer through SRC/MAPK signaling, showing that combinatorial SRC/MEK inhibition is effective in treating mesenchymal-like HG-SOC.

bioRxiv · Jun 19, 2020Cancer Biology

Cannabinoid Receptor 2 (CB2) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes

Y. Saroz, D. T. Kho, M. Glass, S. Graham, N. L. Grimsey

This paper investigates CB2 receptor signaling in human primary leukocytes, revealing complex G protein interactions and cytokine secretion pathways.

ACS Pharmacology & Translational Science · Oct 1, 2019Peer-reviewedCell Biology

The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogues

S. Banister, R. Kevin, L. Martin, A. Adams, C. Macdonald, J. Manning, B. Rochelle, C. Michael, M. Stevens, I. McGregor, M. Glass, M. Connor, R. Gerona

This study synthesizes and characterizes new psychoactive substances (NPS) and evaluates their pharmacology at cannabinoid receptors.

bioRxiv · Oct 3, 2018Pharmacology & Toxicology